Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Studieöversikt

Detaljerad beskrivning

Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.

Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.

Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.

This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Studietyp

Interventionell

Inskrivning (Beräknad)

60

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 90 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age between 18 and 90 years old
  • ASA status I to III inclusively
  • Planned lower body surgery under spinal anesthesia with chloroprocaine
  • Signed informed consent form

Exclusion Criteria:

  • Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
  • Preexisting neuropathy or nerve block that could interfere with study assessments
  • Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
  • Preoperative use of corticosteroids
  • Patient refusal
  • Inability to consent
  • Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
  • Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
  • Perioperative intravenous dexmedetomidine administration
  • Conversion to general anesthesia
  • Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
  • Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Intravenous dexamethasone

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine

Andra namn:
  • Dekadron
Placebo-jämförare: Intravenous normal saline

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine

Andra namn:
  • Placebo

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Regression of sensory block by 2 dermatomes
Tidsram: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level

At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Duration of motor block
Tidsram: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Time until the first observable regression of the motor block
Tidsram: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale.

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Onset of sensory block
Tidsram: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation

Up to 30 minutes following spinal anesthesia
Onset of motor block
Tidsram: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale

Up to 30 minutes following spinal anesthesia
Quality of motor block
Tidsram: Up to 30 minutes following spinal anesthesia

Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block.

The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block.

Up to 30 minutes following spinal anesthesia
Opioid consumption
Tidsram: At recovery room discharge, approximately one hour after the end of surgery

Total dose of opioids

At recovery room discharge, approximately one hour after the end of surgery
Antiemetic consumption
Tidsram: At recovery room discharge, approximately one hour after the end of surgery

Total dose of antiemetics

At recovery room discharge, approximately one hour after the end of surgery
Incidence of hypotension
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Systolic blood pressure lower than 90 mm Hg

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of bradycardia
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Heart rate slower than 50 beats per minute

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of nausea
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of nausea reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of vomiting
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of retching or vomiting reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of itching
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of itching reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of urinary retention
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of urinary retention reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of shivering
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of shivering reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of headache
Tidsram: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of headache reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Quality of postoperative recovery
Tidsram: At 24 hours after the surgery

QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome).

At 24 hours after the surgery
Intensity of nausea/vomiting
Tidsram: At 24 hours after surgery

Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Pain intensity
Tidsram: At 24 hours after surgery

Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Quality of sleep
Tidsram: At 24 hours after surgery

Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Surgeon's satisfaction towards spinal anesthesia
Tidsram: At the end of surgery, on the day of randomization

Unsatisfied or satisfied

At the end of surgery, on the day of randomization

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Stephan Williams, MD, PhD, Santé Québec - CHUM

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 november 2027

Avslutad studie (Beräknad)

1 november 2027

Studieregistreringsdatum

Först inskickad

18 september 2026

Först inskickad som uppfyllde QC-kriterierna

18 september 2026

Första postat (Faktisk)

23 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 oktober 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera